stoxline Quote Chart Rank Option Currency Glossary
  
Lexicon Pharmaceuticals, Inc. (LXRX)
0.7849  0.044 (5.88%)    02-14 16:00
Open: 0.7511
High: 0.827
Volume: 2,598,492
  
Pre. Close: 0.7413
Low: 0.7501
Market Cap: 284(M)
Technical analysis
2025-02-14 4:49:36 PM
Short term     
Mid term     
Targets 6-month :  1.08 1-year :  1.27
Resists First :  0.92 Second :  1.09
Pivot price 0.77
Supports First :  0.66 Second :  0.54
MAs MA(5) :  0.73 MA(20) :  0.79
MA(100) :  1.1 MA(250) :  1.59
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  18.9 D(3) :  12.7
RSI RSI(14): 50.4
52-week High :  3.73 Low :  0.62
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LXRX ] has closed below upper band by 47.3%. Bollinger Bands are 36.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.83 - 0.83 0.83 - 0.83
Low: 0.74 - 0.75 0.75 - 0.75
Close: 0.78 - 0.78 0.78 - 0.79
Company Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Headline News

Tue, 07 Jan 2025
Strong week for Lexicon Pharmaceuticals (NASDAQ:LXRX) shareholders doesn't alleviate pain of five-year loss - Simply Wall St

Mon, 06 Jan 2025
Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Yahoo Finance

Mon, 30 Dec 2024
Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33% - Yahoo Finance

Fri, 20 Dec 2024
Lexicon Pharma Receives FDA Rejection for Diabetes Drug Zynquista, Shifts Focus to Pain Treatment Pipeline - StockTitan

Mon, 25 Nov 2024
Lexicon Pharmaceuticals CEO to Present at Two Major Healthcare Conferences in December - StockTitan

Fri, 22 Nov 2024
Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 361 (M)
Held by Insiders 1.8214e+008 (%)
Held by Institutions 1.1 (%)
Shares Short 31,280 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.1055e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -3 %
Return on Assets (ttm) 639.5 %
Return on Equity (ttm) -44.2 %
Qtrly Rev. Growth 5.23e+006 %
Gross Profit (p.s.) 790.48
Sales Per Share -109.75
EBITDA (p.s.) -5.45726e+007
Qtrly Earnings Growth -0.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.98
Stock Dividends
Dividend 0
Forward Dividend 3.91e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android